Conference Coverage
Conference Coverage
How to incorporate the gender wage gap into contract negotiations
PHILADELPHIA – Don’t view a woman asking for something as demanding or harsh when a male asking for the same exact...
Conference Coverage
Calcium supplement use linked to cancer death
PHILADELPHIA – Multiply dairy servings by 300 g to get a ballpark estimate of calcium intake.
Conference Coverage
Back to the drawing board for MPN combo
NEWPORT BEACH, CALIF. – Ruxolitinib plus decitabine won’t proceed to a phase 3 trial for the treatment of accelerated or blast phase...
Conference Coverage
ENCORE-601: Entinostat/pembrolizumab safe, active for melanoma
ATLANTA – Combined therapy with the HDAC inhibitor entinostat and the PD-1 inhibitor pembrolizumab has significant clinical activity and...
Conference Coverage
MAT access helps address opioid use disorder
PHILADELPHIA – Incarceration is an accelerant in the crisis of opioid use disorder.
Conference Coverage
C3 inhibitor shows potential in PNH and AIHA
GLASGOW – Researchers presented early results from the PADDOCK and PLAUDIT trials, showing that APL-2 significantly increased hemoglobin levels...
Video
Volunteerism: How and why to do it, according to Dr. Eileen Barrett
PHILADELPHIA – Ideas for volunteering that beat packing penicillin in a backpack.
Conference Coverage
Creating CAR T-cell therapies for T-cell malignancies
NEWPORT BEACH, CALIF. – Dr. John F. DiPersio discusses preclinical research testing CAR T-cell therapies in T-cell malignancies.
Conference Coverage
Liquid biopsy falls short for isolated brain lesions in lung cancer
GENEVA – Plasma circulating tumor DNA analysis detected molecular abnormalities in almost all patients with systemic...
Conference Coverage
Novel CAR T, anti-PD-1 combo shows promise in MPD
ATLANTA – Intrapleurally administered, mesothelin-targeted CAR T-cell therapy combined with PD-1 inhibition showed antitumor activity without...
Conference Coverage
Direct-to-consumer genetic testing fraught with validity concerns
PHILADELPHIA – Dr. Andrew Coyle discusses the latest issues with DTC testing.